Home / 2014 / January (page 9)

Monthly Archives: January 2014

Editor’s Note, DCMS #171: Dapagliflozin Approval

Last Friday, the FDA approved the SGLT2 inhibitor dapaglifozin. This is the second drug in the SGLT2-I class and so now the battle of superiority, dapagliflozin versus canagliflozin, begins. There will also be extra pressure from the DPP4-I companies to downplay the value of this drug class. This week, in …

Read More »

FDA Approves New Diabetes Drug

FDA Approves New Diabetes Drug. See this week’s Item #1. Truebalance and Truetrack Blood Glucose Meters by Nipro Diagnostics: Recall – Incorrect Factory-set Measure. Meters have an incorrect factory-set unit of measure that displays the glucose result in mmol/L rather than mg/dl. www.NiproDiagnostics.com/product-notice

Read More »

Retina Camera

retinacameraimage

Retina Camera  A new optical device the size of a hand held video camera from the Massachusetts Institute of Technology can scan an entire retina in seconds. This device combines ultra high-speed 3D imaging, a tiny micro-electro mechanical systems mirror for scanning, and corrective techniques for unintentional movements in a …

Read More »

Universal Food Diary

Fooddiaryimage

Universal Food Diary  Here is a very basic one page food diary from dLife all your patients can use. Have them fill it out prior to their appointment. Having your patients write down their daily food intake can have a huge impact on their blood sugars. Food Diary(pdf)   

Read More »

Asthma Drug to Treat Diabetes and Obesity

Obese mice treated with the asthma drug amlexanox had a renewed sensitivity to catecholamines, utilized excess energy, and returned to normal size, according to Alan R. Saltiel, PhD, University of Michigan. "There is considerable evidence to suggest that in states of obesity, adipose tissue becomes less sensitive to catecholamines because …

Read More »

Prostate Cancer Death Risk Higher with Diabetes

A team led by Laurent Azoulay, MD, of McGill University in Montreal, studied 11,920 men newly diagnosed with non-metastatic prostate cancer (PCa). The cohort included 1,132 men (9.5%) with pre-existing type 2 diabetes. A total of 3,605 deaths, including 1,792 from PCa, occurred during a mean 4.7 years of follow-up. …

Read More »